Zenas Biopharma Inc (ZBIO) FinancialsZBIOZenas Biopharma Inc

Evaluating the bottom line, Zenas BioPharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7765.90%, while the net margin is -11145.60%. These profitability ratios, combined with a Return on Equity (ROE) of -199.04%, provide a clear picture of how effectively ZBIO converts its operational activities into shareholder value.

In the context of the broader market, ZBIO competes directly with industry leaders such as NTLA and ANIP. With a market capitalization of $1.74B, it holds a leading position in the sector. When comparing efficiency, ZBIO's gross margin of 100.00% stands against NTLA's 100.00% and ANIP's 54.97%. Such benchmarking helps identify whether Zenas BioPharma, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $111.46 million in Q2 2026, with a forward P/E ratio of 0, indicating no earnings expected in the near term. Despite a gross margin of 100% in previous quarters, the financial outlook remains concerning due to escalating losses.